Boston, MA 08/19/2014 (wallstreetpr) – Eli Lilly and Co (NYSE:LLY) received positive news on its insulin injection that can be used to control sugar levels in diabetic patients after the FDA granted it tentative approval. The drug named, Basaglar, can be used to provide long lasting blood sugar control when patients are taking their meals or during night time. Eli Lilly has also pointed out that the drug is not intended’ for the treatment of diabetic ketoacidosis. Basaglar has the same amino acids as currently being used insulin Glargine product and was approved for use with KwikPen, a pre-filled dosing device.
Sanofi’s Stand off
The next challenge that Eli Lilly will have to sort out in relation to the new drug is a litigation filed by Sanofi SA (ADR)(NYSE:SNY) against the same; the drug remains under an automatic stay order of up to 30 months awaiting the sorting out of the standoff. Sanofi is reportedly suing Eli Lilly on claims it infringed its seven patents related to insulin and devices used to deliver the drug. Eli Lilly and Co (NYSE:LLY)’s Glargine product is already considered’ biosimilar in other regions such as Europe where it also received approval although it is not considered’ biosimilar in the U.S.
Eli Lily Looking for a Global trade Name
The FDA is restricted to giving a final approval, until the end of the 30-month period. It may also approve the drug if the issue is sorted early. The tentative approval according to Eli Lilly and Co (NYSE:LLY) is another milestone on the company’s push to provide alternative options for patients suffering from diabetes across the globe, especially those in need of basal insulin treatment.
‘Basaglar’ the trade name was granted approval by the FDA and looks set to be used in the U.S markets once the product receive the final approval. Eli Lilly and Co (NYSE:LLY) and Boehringer Ingelheim are reportedly targeting a global trade name for the drug that will be used to market it outside the U.S
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact email@example.com.